biOasis enters into agreement with MedImmune

Vancouver's biOasis Technologies Inc. (TSX-V: BTI) announced this morning it has entered into a research and evaluation agreement with MedImmune, the global biologics arm of ...

Vancouver's biOasis Technologies Inc. (TSX-V: BTI) announced this morning it has entered into a research and evaluation agreement with MedImmune, the global biologics arm of AstraZeneca.

Under the agreement, biOasis will conduct experiments with the objective of demonstrating the usefulness of its Transcend technology to MedImmune, at MedImmune's expense.

"The work we have done to date on Transcend and the milestones we have achieved all support driving us to agreements such as the one we are announcing today," said Rob Hutchison, CEO of biOasis, calling MedImmune a "leader in the development of biologics."

Hutchison told Business in Vancouver that the Transcend technology essentially transports therapeutic compounds to parts of the brain that would be otherwise unreachable.

He also said that biOasis has additional collaborative agreements with Vancouver's BRI Pharmaceutical Research Inc., Wax-it Histology Services and St. Paul's Hospital.

Formed in 2007, BiOasis is a Vancouver-based biopharmaceutical company specializing in the development of technologies for the diagnosis and treatment of central nervous system diseases and disorders. The company describes Transcend as a "protein vector to shuttle existing therapeutic drugs across the blood-brain barrier."

In November 2010, the company sponsored a research agreement with the National Research Council (NRC) of Canada to investigate the effectiveness of this technology. In January of 2011, the NRC confirmed that Transcend is effective at shuttling compounds across the blood-brain barrier.

Neither company has released financial details of this agreement.

ecrawford@biv.com

@EmmaCrawfordBIV

comments powered by Disqus

More from Technology

France turns to Vancouver in hunt for tech talent

In a new push to develop its innovation sector, French government woos B.C. startups

Read Article

Warning! Disruption ahead: Yahoo’s ex-chief innovator

Author Salim Ismail advises businesses to take small steps to adapt to major changes

Read Article

Ottawa shortlists B.C. partnership backed by Telus for $950m supercluster strategy

Read Article

Infographic: 10 key considerations when launching a product

From market analysis to design to maintenance, this infographic has some suggestions to help with a successful product launch

Read Article

Virtual world making more inroads in property marketing

Software advancements, millennials creating major sales shift

Read Article

Subscribe to our mailing lists

You may withdraw your consent at any time.

* indicates required

Newsletters

* You can modify your newsletter subscriptions at the bottom of any newsletter you receive.
Business in Vancouver Media Group
303 West 5th Avenue, Vancouver, British Columbia
V5Y 1J6 · Canada
604-688-2398
×